Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Detrusor Overactivity, Overactive Bladder
Interventions
Placebo, solifenacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
New York, New York • West Reading, Pennsylvania
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
112
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 99 more
Conditions
Overactive Bladder
Interventions
TENS
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
55 Years to 100 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Overactive Bladder
Interventions
PTNS plus solifenacin, Placebo
Other
Lead sponsor
Bay State Clinical Trials, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Watertown, Massachusetts
Conditions
Overactive Bladder
Interventions
dexmecamylamine, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
125
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 109 more
Conditions
Overactive Bladder
Interventions
OnabotulinumtoxinA 100 Units
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Greensboro, North Carolina • Winston-Salem, North Carolina
Conditions
Overactive Bladder
Interventions
Avatar group, No Avatar group
Other
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
55 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Conditions
Urinary Incontinence, Detrusor Overactivity, Urinary Urgency, Urge Urinary Incontinence
Interventions
Botulinum Toxin A, bladder detrusor muscle injection, Vehicle saline as placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Conditions
Overactive Bladder, Overactive Detrusor, Urgency-Frequency Syndrome, UTI
Interventions
Extended Urine Culture
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Weston, Florida
Conditions
Overactive Bladder
Interventions
Toviaz
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Urinary Bladder, Overactive, Pelvic Organ Prolapse
Interventions
OnabotulinumtoxinA 100 UNT, Injectable saline
Drug · Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting Phase 4 Interventional Accepts healthy volunteers

Bladder Botox UTI Antibiotic Prophylaxis

NCT06387329
Conditions
Overactive Bladder, Bladder Pain Syndrome
Interventions
Nitrofurantoin 100 MG
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational

A Cost Analysis of Interstim Therapy

NCT00200031
Conditions
Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency)
Interventions
Interstim therapy
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Overactive Bladder
Interventions
conjugated estrogen
Drug
Lead sponsor
Loyola University
Other
Eligibility
55 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
58
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lidocaine Patches Prior to Percutaneous Nerve Evaluation

NCT05783219
Conditions
Overactive Bladder, Urge Incontinence, Fecal Incontinence
Interventions
Lidocaine patch, Placebo
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky
Conditions
Voiding Disorders, Overactive Bladder, Urinary Incontinence
Interventions
Lidocaine gel 2%, Standard lubricant gel
Drug · Other
Lead sponsor
Atlantic Health System
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Morristown, New Jersey
Terminated Phase 4 Interventional Results available

OnabotulinumtoxinA Bladder Injection Study

NCT03523091
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Incontinence, Urinary Frequency/Urgency, Urinary Bladder, Overactive
Interventions
OnabotulinumtoxinA 100Unit Injection
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
Overactive Bladder
Interventions
Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification
Drug · Behavioral
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Burlington, Massachusetts
Conditions
Overactive Bladder Syndrome
Interventions
PTNS
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Completed Phase 1Phase 2 Interventional Results available

Botulin-A Toxin Instillations and Overactive Bladder

NCT00583219
Conditions
Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
Interventions
Botulinum-A toxin, Dimethyl sulfoxide (DMSO)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Overactive Bladder
Interventions
Vibegron, placebos, Tolterodine Tartrate ER
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
107
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 90 more
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Conditions
Overactive Bladder
Interventions
Fesoterodine fumarate, Placebo, Percutaneous Tibial Nerve Stimulation (PTNS)
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona